Five-market expansion plan: 2,590 contacts, 204 strategies, and a combined revenue opportunity exceeding £1.17 million per year — with France in the research pipeline.
Brainzyme's ADHD partnership strategy spans five markets — four active and one in the research pipeline — with a combined ADHD population of ~24 million adults. This master report unifies UK, US, Canada, Germany, and France into a single strategic view.
No supplement brand is systematically partnering with ADHD practitioners. No branded nootropic stack exists on Fullscript (100,000+ practitioners) or Simplycure (10,000+ practitioners). No supplement brand sponsors ADDitude Magazine (4M+ monthly visitors), CHADD conferences, or exhibits at Paracelsus Messe. Germany’s 47,000 Heilpraktiker — a practitioner channel with no equivalent anywhere else — are actively selling supplements but no branded nootropic targets them. France’s “médecine douce” culture and 5.5% VAT rate create an exceptionally favourable entry. Brainzyme has a first-mover window across five markets for a combined setup cost of approximately £17,000.
Three scenarios across four active markets, converted to GBP for comparison. France (pipeline) not yet modelled.
| Scenario | UK (GBP) | US (USD→GBP) | Canada (CAD→GBP) | Germany (EUR→GBP) | France | Combined (GBP) |
|---|---|---|---|---|---|---|
| Floor | £300,090 | $603,132 → £467K | $106,860 → £61K | €73K → £63K | Research Phase | £891,000 |
| Most Likely | £380,000 | $785,256 → £608K | $140,088 → £80K | €120K → £103K | £1,171,000 | |
| Ceiling | £485,310 | $971,328 → £752K | $174,516 → £99K | €196K → £168K | £1,505,000 | |
| Setup Cost | <£4,000 | ~$8,150 → £6,300 | ~$5,900 → £3,400 | ~€3,700 → £3,200 | ~€4–10K (est.) | ~£17,000 |
Combined Most Likely annual net revenue: £1,171,000 (France not yet modelled)
Each market has unique dynamics, regulatory requirements, and channel strengths.
How each sale converts to net revenue across all markets.
| Line Item | UK (GBP) | US (USD) | Canada (CAD) | Germany (EUR) | France (EUR est.) |
|---|---|---|---|---|---|
| Customer pays | £30.00 | $39.00 | $53.00 | €35.00 | €35.00 |
| Partner margin (30%) | -£9.00 | -$11.70 | -$15.90 | -€10.50 | -€10.50 |
| Tax | -£3.50 (20% VAT) | $0.00 (exempt) | -$6.36 (12% GST+HST) | -€1.60 (7% MwSt) | -€1.28 (5.5% TVA) |
| Net to Brainzyme | £17.50 | $27.30 | $30.74 CAD | €22.90 (~£19.63) | €23.22 (~£20.02) |
Germany’s 7% MwSt and France’s 5.5% TVA on supplement capsules are massive advantages vs the UK’s 20% VAT. Net per purchase in Germany (€22.90) is 12% higher than the UK (£17.50). France would deliver the highest net margin in Europe at €23.22. The US remains the best net margin overall due to complete supplement tax exemption.
How the same channels perform differently across markets.
| Channel | UK Purch/Mo | US Purch/Mo | CA Purch/Mo | DE Purch/Mo | Conversion Rate |
|---|---|---|---|---|---|
| Naturopathic / Nutritional Therapists | 13 | 34 | 28 | 3 (Ernährungsberater) | 23-27% |
| Functional Medicine | — | 35 | — | 5 | 27.5% |
| Private ADHD Clinics (solo) | 20 | 14 | 1.3 | — | 2.5-4.5% |
| Private ADHD Clinics (multi) | 20 | 34 | 7.5 (virtual) | — | 2.5-4.5% |
| ADHD Coaches | 4 | 1.3 | 0.9 | 3 | 7.5-11% |
| Support Groups | 2 | 2 | 3 | — | 12-15% |
| Heilpraktiker | — | — | — | 5 | High (supplement-native) |
| HP Psychotherapie | — | — | — | 2 | Moderate |
| Podcasts | varies | varies | varies | 10 (avg) | 1.5-3% of listeners |
Germany introduces an entirely new top-tier channel: Heilpraktiker. These 47,000 practitioners already sell supplements as a core revenue stream — 9/10 sample-friendliness. No other market has this channel. In France, naturopathes (6,000–8,000) and the Simplycure platform (10,000+ practitioners) will serve a similar function. NDs and functional medicine remain the highest-converting channel in every market where they exist.
2,590 total contacts across four markets, ready for outreach. France database pending.
| Channel | UK | US | CA | DE | FR | Total |
|---|---|---|---|---|---|---|
| Private ADHD Clinics | 430 | 405 | 15 | — | — | 850 |
| Support Groups | 381 | — | — | — | — | 381 |
| Coaches & Therapists | 95 | 303 | 6 | 67 | — | 471 |
| Nutritional Therapists / NDs | 88 | 31 | 20 | 129 | — | 268 |
| Functional Medicine | — | 10 | — | 80 | — | 90 |
| Organisations & Platforms | — | — | 9 | — | — | 9 |
| Heilpraktiker | — | — | — | 392 | — | 392 |
| HP Psychotherapie | — | — | — | 99 | — | 99 |
| Podcasts & Media | — | — | — | 30 | — | 30 |
| TOTAL | 994 | 749 | 50 | 797 | — | 2,590 |
Each market has different regulatory requirements and timelines.
UK Public Authority registered. GMP & HACCP certified manufacturing in Scotland. Fully compliant. No further regulatory action needed.
Status: ActiveUnder DSHEA (1994), supplements require no pre-market FDA approval. Simple online registration of manufacturing facility + product notification. Structure/function claims allowed with standard disclaimer.
Status: Simple form, near-instantCanada requires a Natural Product Number (NPN) before any supplement can be legally sold. Products can be seized at the border without NPN. Timeline: 90–310 days. Bilingual labelling mandatory.
Status: Legal blockerSupplements are food products under NemV. Mandatory notification to BVL (Bundesamt für Verbraucherschutz). No pre-market approval needed. German-language labelling required. EU Responsible Person required post-Brexit. 7% MwSt on capsules. Same EFSA health claims as UK.
Status: Notification + EU RP neededSupplements require DGCCRF notification via Téléicare platform. French positive list of authorised plant substances (540+). EU Responsible Person required. 5.5% TVA on supplement capsules. Loi Anti-cadeaux restricts sampling to unregulated practitioners only (naturopathes, coaches — not doctors, pharmacists).
Status: Research phaseExtraordinary return on investment across all active markets.
| Item | UK | US | Canada | Germany | France (est.) |
|---|---|---|---|---|---|
| Product samples | ~£1,500 | ~$3,000 | ~$1,600 CAD | ~€1,750 | ~€1,500 |
| Shipping | ~£1,000 | ~$1,500 | ~$800 CAD | ~€1,150 | ~€1,000 |
| Regulatory | £0 | ~$500 (FDA) | ~$500 CAD (NPN fee) | ~€200 (BVL) | ~€0 (DGCCRF free) |
| Labelling / Compliance | £0 | ~$2,000 | ~$2,500 CAD (bilingual) | ~€600 (German) | ~€600 (French) |
| EU Responsible Person | — | — | — | Shared (see FR) | ~€3,000–8,000/yr |
| Landing page / Portal | ~£500 | ~$1,000 | ~$500 CAD | — | — |
| Other | — | ~$150/yr (Gmail) | — | — | — |
| Total Setup | <£4,000 | ~$8,150 | ~$5,900 CAD | ~€3,700 | ~€4–10K |
| Human resource | 1 person for warm calls (same person across all markets). Claude AI handles outreach. | ||||
~6,900% Return on Investment
£1,171,000 combined revenue / ~£17,000 total setup cost. Even the Floor scenario (£891K) returns ~5,200%.
The two highest-leverage platform plays across US, Canada, and Europe.
Fullscript is the dominant practitioner supplement dispensary platform in North America. No branded nootropic stack is currently listed — this is a first-mover gap.
Simplycure is France’s dominant practitioner dispensary platform. Practitioners build supplement protocols, clients purchase through the platform, and practitioners earn 15–20% commission. Getting listed is the #1 infrastructure play for France.
First-mover advantages that exist right now across all five markets.
110,000+ practitioners across two platforms use Fullscript/Simplycure daily to recommend supplements. Zero branded nootropic stacks are listed on either. Brainzyme would be first in both.
ADDitude Magazine (4M+ monthly visitors, 350K email subscribers) carries no supplement brand advertising or sponsorship. Wide-open channel.
The two major ADHD professional conferences (US and Canada) have no supplement brand exhibitor presence.
Germany’s unique practitioner channel already sells supplements as a core revenue stream. BRAINEFFECT (the local market leader at €20M) does retail and influencer — not practitioner partnerships. This entire channel is untouched.
French competitors (Dynveo, Pileje, Nutergia, NHCO) offer single ingredients or generic cognitive products. None positions specifically for ADHD/focus. Brainzyme’s 3-formula system is unique in this market.
No supplement brand is systematically contacting ADHD practitioners with personalised outreach, free samples, and partnership proposals in any of the five markets.
The proven model: 994 contacts, 57 strategies, 14 channel categories.
The scale opportunity: 749 contacts, 57 strategies, 11 channel categories.
The emerging market: 50 contacts, 35 strategies, two-phase approach (pre-NPN / post-NPN).
Canada's NPN is a legal requirement, not optional. Without it, products cannot be sold, shipped, or listed on Fullscript. Timeline: 90–310 days.
The European powerhouse: 797 contacts, 55 strategies, 13 channel categories. Unique Heilpraktiker channel with 47,000 addressable practitioners.
Post-Brexit, Brainzyme needs an EU-based Responsible Person for both Germany and France. This is a shared cost (€3,000–8,000/yr). BVL notification is mandatory but straightforward (online form, no approval process). German-language labelling required.
The research market: extensive market research completed; financial model, strategy document, and contact database still to be built.
5
Naturopathes, TDAH Coaches, Associations, Simplycure, Influencers
7
Sophrologues, Nutritionnistes, Podcasts, Life Coaches, Hypnothérapeutes, FM, Conferences
3
Market research, B2B channel assessment, Competitive landscape
Global view of effort vs impact across all five markets.
Combined 12-month roadmap across all five markets.
UK Begin AI-powered email outreach to 994 contacts. Set up Gmail Workspace, booking page, landing page. Send first sample packs.
US Complete FDA facility registration + product notification online. Apply to Fullscript for US brand listing.
CA Engage NHP regulatory consultant. Begin NPN application. Start bilingual labelling development.
DE Appoint EU Responsible Person (shared with France). Submit BVL notification. Begin German-language labelling. Set up Gmail for German outreach.
US Launch personalised outreach to 749 contacts (NDs, FM, clinics, coaches). Send sample packs to HIGH-priority targets. Create US landing page.
DE Launch personalised outreach to 797 contacts. Priority: 392 Heilpraktiker first (highest conversion), then Ernährungsberater and FM. Send sample packs with German-language materials.
CA Send information packs to top 10 NDs. Build “coming to Canada” landing page. Contact CADDAC for partnership discussions.
FR Build France financial model. Write partnership strategies document. Build naturopathe and coach contact database. Verify ingredients against French positive plant list. Apply to Simplycure.
UK US DE First active partnerships producing revenue in three markets. Refine outreach based on reply data.
CA Attend CADDRA Hybrid Intensive (Halifax, June 2026). Network with Canadian ADHD professionals.
DE First 30–50 Heilpraktiker partners active. Approach BDH/VDH for association partnerships. Register for Paracelsus Messe and AG ADHS Kongress.
UK US DE Scale successful channels. Podcast sponsorships (UK). ADDitude/CHADD (US). Heilpraktiker association partnerships (DE). Target 50+ active partners per market.
FR Complete DGCCRF notification. Launch naturopathe and TDAH coach outreach. French-language materials live. Simplycure listing active. Begin sending sample packs.
CA NPN approval. Immediately apply to Fullscript. Begin shipping to Canada. Activate pre-warmed ND partnerships.
ALL All five markets active. Year 1 targets: UK ~95, US ~112, CA ~25, DE ~100 partners. France initial partners forming. Combined £1.17M+ run-rate from 4 modelled markets.
Key risks across all five markets and mitigation strategies.
| Risk | Market | Likelihood | Impact | Mitigation |
|---|---|---|---|---|
| NPN application delayed beyond 310 days | Canada | Medium | High | Engage experienced consultant. Classify as Class I if possible. |
| NPN application rejected | Canada | Low | Very High | Pre-screen with consultant. Ensure ingredient dossiers meet monographs. |
| Partner attrition (10-15% annual) | All | High | Medium | Offset with new partner acquisition. Re-engage dormant partners. |
| Fullscript/Simplycure listing rejected | US/CA/FR | Low | High | Ensure GMP certification, full documentation. Alternative: direct wholesale. |
| BRAINEFFECT activates practitioner channel | Germany | Medium | Medium | First-mover advantage. Build relationships before Schwabe leverages pharmacy network. |
| French ingredient rejected by DGCCRF | France | Medium | High | Pre-verify all ingredients against positive plant list. Engage French regulatory consultant. |
| EU Responsible Person setup delay | DE/FR | Medium | Medium | Begin RP appointment in Month 1. Multiple service providers available. |
| Loi Anti-cadeaux compliance issue | France | Low | High | Only sample to unregulated practitioners. Legal review of all partnerships. |
| Low outreach conversion rate | All | Medium | Medium | A/B test subject lines. Increase personalisation. Iterate based on reply data. |
| Currency fluctuation (GBP/USD/CAD/EUR) | All | Medium | Low | Revenue is net-positive in all scenarios. Pricing adjustable. |
| Competitor enters practitioner partnerships | All | Low | Medium | First-mover advantage. Build relationships before competitors identify the channel. |
| Regulatory claim challenge (ASA/FTC/BVL/DGCCRF) | All | Medium | Medium | EFSA-authorised claims only. No disease claims. Compliance review of all materials. |
The most important next steps across all five markets, in order of priority.
204 strategies across four markets (France pending), organised by channel category.
| Category | UK | US | CA | DE | FR |
|---|---|---|---|---|---|
| Private ADHD Clinics | 8 | 8 | 6 | — | — |
| NDs / Nutritional Therapists / FM | 6 | 10 | 7 | 11 | — |
| Heilpraktiker / HP Psych | — | — | — | 12 | — |
| Coaches & Therapists | 5 | 6 | 4 | 4 | — |
| Support Groups / Charities | 7 | 5 | 6 | — | — |
| Platforms (Fullscript, etc.) | 2 | 5 | 5 | 3 | — |
| Media, Podcasts, Influencers | 8 | 8 | 4 | 8 | — |
| Conferences & Events | 4 | 5 | 3 | 3 | — |
| Universities / Corporate | 6 | 4 | — | — | — |
| NHS / Institutional | 5 | — | — | — | — |
| Regulatory / Strategic / Market-Specific | 3 | 3 | 3 | 5 | — |
| Paid Opportunities | 3 | 3 | — | — | — |
| Adjacent Channels (OT, Pharmacy, Digital) | — | — | — | 9 | — |
| TOTAL | 57 | 57 | 35 (+ 2-phase) | 55 | Pending |
Key published data underpinning the financial models across all markets.
| Data Point | Figure | Source | Year |
|---|---|---|---|
| ND visits per week | ~30 | AANP Membership Survey / PMC529271 | 2012/2004 |
| ND botanical prescription rate | 43-51% | PMC (300,483 visits study) | 2014 |
| NDs recommending supplements | 91% | Nutritional Outlook | 2019 |
| FM daily patient volume | 5-10/day | IFM Practitioner Survey | 2015 |
| Psychiatrist daily volume | 10-20/day | APA Psychiatric Services | 2019 |
| ICF avg clients per coach | 12.2 | ICF Global Coaching Study | 2023 |
| Fullscript practitioners | 100,000+ | Fullscript | 2025 |
| Fullscript adherence improvement | 25% → 37%+ | PMC8325502 | 2021 |
| Healthcare cold email reply rate | 5.2-7.5% | Digital Bloom | 2025 |
| FMCG sampling trial-to-purchase | 10-20% | MarketingSherpa / Eventeem | Various |
| US ADHD adult prevalence | ~6.8% (~16.5M) | JAMA Psychiatry | 2023 |
| Canada ADHD adult prevalence | 4-6% (~1.8M) | CADDAC / PMC9406225 | 2022-24 |
| Germany ADHD adult prevalence | ~3% (~2M) | Epidemiological studies / KiGGS Wave 2 | 2014-2017 |
| Germany ADHD diagnosis gap | 0.2–0.4% diagnosed vs 3% est. | Deutsches Ärzteblatt / PMC5378979 | 2009-2014 |
| Germany Heilpraktiker count | ~47,000 | Statistisches Bundesamt | 2017 (est. 2025) |
| Germany supplement market | USD 5.36B | Coherent Market Insights | 2025 |
| Germany supplement CAGR | 9.2% | Grand View Research | 2025-2030 |
| Germany MwSt on supplement capsules | 7% (reduced) | VAT Update / Taxology | 2026 |
| Germany herbal medicine usage | 75% of adults | Frontiers in Medicine | 2024 |
| France ADHD adult prevalence | 2.5–3.5% (~1.3–1.8M) | Epidemiological estimates | 2024 |
| France supplement market | €2.6–2.8B | Industry estimates / Synadiet | 2024 |
| France TVA on supplement capsules | 5.5% (reduced) | French tax law | 2026 |
| France supplement usage | 58% of adults | Synadiet | 2024 |
| Simplycure practitioners | 10,000+ | Simplycure | 2025 |
| Canadian NDs (total) | ~3,000+ | CAND | 2025 |
| Supplement revenue boost for FM | 20-25% of practice revenue | Pabau | 2025 |
| Gap | Market | Impact | Mitigation |
|---|---|---|---|
| No ADHD coach → purchase conversion data | All | Coach revenue may be off | Conservative rates used (11-18%) |
| No Brainzyme-specific conversion data in US/CA/DE/FR | US/CA/DE/FR | All projections modelled | Compare vs UK actuals when available |
| Heilpraktiker ADHD subset size unknown | Germany | Volume per partner uncertain | Used conservative estimates; actual addressable may be higher |
| France: no financial model yet | France | Revenue not projectable | Build model as next step; per-purchase economics estimated |
| NPN pre-regulatory impact unknown | Canada | Clinic conversion may be too high | Used conservative 2.5% for CA clinics |
| Simplycure conversion data not public | France | Platform revenue uncertain | Use Fullscript data as proxy |
| AANP visit data is from 2012 | US | ND volumes may differ now | Corroborated with PMC 2014 study |
Complete list of all files produced for the ADHD partnership project.
| Market | File | Description | Entries |
|---|---|---|---|
| United Kingdom | |||
| UK | ADHD-Partnership-Strategies.md | 57 strategies, 14 categories | — |
| UK | ADHD-Partnership-Strategy-Report.html | Visual HTML report | — |
| UK | Finalists/Finalists-Private-Clinics.csv | Private ADHD clinics database | 430 |
| UK | Finalists/Finalists-Support-Groups.csv | Support groups database | 381 |
| UK | Finalists/Finalists-Coaches-Therapists.csv | Coaches & therapists database | 95 |
| UK | Finalists/Finalists-Nutritional-Therapists.csv | Nutritional therapists database | 88 |
| United States | |||
| US | US/ADHD-Partnership-Strategies-US.md | 57 strategies, 11 categories | — |
| US | US/ADHD-Financial-Model-US.md | Full financial model with sources | — |
| US | US/ADHD-Partnership-Strategy-Report-US.html | Visual HTML report | — |
| US | US/Finalists/Finalists-Private-Clinics.csv | Private ADHD clinics database | 405 |
| US | US/Finalists/Finalists-Coaches-Therapists.csv | Coaches & therapists database | 303 |
| US | US/Finalists/Finalists-Naturopathic-Doctors.csv | Naturopathic doctors database | 31 |
| US | US/Finalists/Finalists-Functional-Medicine.csv | Functional medicine database | 10 |
| Canada | |||
| CA | Canada/ADHD-Partnership-Strategies-Canada.md | 35 strategies, 7 categories | — |
| CA | Canada/ADHD-Financial-Model-Canada.md | Full financial model with sources | — |
| CA | Canada/ADHD-Partnership-Strategy-Report-Canada.html | Visual HTML report | — |
| CA | Canada/Finalists/Finalists-Canada-All-Channels.csv | All-channel database | 50 |
| Germany | |||
| DE | Germany/ADHD-Partnership-Strategies-Germany.md | 55 strategies, 13 channels | — |
| DE | Germany/germany-adhd-market-research.md | Full market research | — |
| DE | Germany/Germany-B2B-Channel-Research.md | 20-channel B2B assessment | — |
| DE | Germany/Germany-Competitive-Landscape-Research.md | Competitive landscape | — |
| DE | Germany/Brainzyme-Partnership-Strategy-Report-Germany.html | Visual HTML report | — |
| DE | Germany/Finalists/Finalists-Heilpraktiker.csv | Heilpraktiker database | 392 |
| DE | Germany/Finalists/Finalists-Ernaehrungsberater.csv | Nutritional therapists database | 129 |
| DE | Germany/Finalists/Finalists-HP-Psychotherapie.csv | HP Psychotherapie database | 99 |
| DE | Germany/Finalists/Finalists-Functional-Medicine.csv | Functional medicine database | 80 |
| DE | Germany/Finalists/Finalists-ADHD-Coaches.csv | ADHD coaches database | 67 |
| DE | Germany/Finalists/Finalists-Podcasts.csv | Podcasts & media database | 30 |
| France (Pipeline) | |||
| FR | France/france-adhd-market-research.md | Full market research | — |
| FR | France/France-B2B-Channel-Research.md | 20-channel B2B assessment | — |
| FR | France/France-Competitive-Landscape-Research.md | Competitive landscape | — |
| FR | Strategies, financial model, database — pending | — | — |
| Master | |||
| ALL | ADHD-Partnership-Strategy-Master-Report.html | This combined report | — |
All files stored under: C:/Users/PC/Desktop/co-work/brainzyme/Partnerships/